Participation in 'The 113th Congress of Japan Society of Aesthetic Surgery,' May 2025
IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ('SBC Medical') today announced that a total of 22 representatives, including Yoshiyuki Aikawa, CEO of SBC Medical, and doctors from Shonan Beauty Clinic, a clinic operated under the management support of SBC Medical Group, a consolidated subsidiary, presented their research findings at 'The 113th Congress of Japan Society of Aesthetic Surgery.'
Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings Incorporated
The Japan Society of Aesthetic Surgery (JSAS), one of Japan's leading professional societies in the field of aesthetic medicine, brings together doctors dedicated to shaping the future of the industry. 'The 113th Congress of Japan Society of Aesthetic Surgery' was held over three days from Wednesday, May 28 to Friday, May 30, 2025, at The Okura Tokyo. Under the theme 'TO BE THE BEST -The Journey of Knowledge Never Ends-,' the congress was chaired in part by Dr. Ayaka Nishikawa, Director of Dermatology Department of Shonan Beauty Group, who served as Vice Chair of the event. The congress provided a valuable platform for in-depth discussions on international trends and future developments in aesthetic medicine, fostering both academic and clinical insights and promoting global collaboration among experts in the field.
Dr. Ayaka Nishikawa, Director of Dermatology Department of Shonan Beauty Group, served as Vice Chair of this Congress
At this congress, a total of 22 representatives from SBC Medical presented their research findings, including Yoshiyuki Aikawa, CEO of SBC Medical, Dr. Daisuke Nakamura, Chief Medical Director of Shonan Beauty Group, Dr. Kazuhiro Igawa, Representative Assistant of Shonan Beauty Group and Dr. Ayaka Nishikawa, who also served as Vice Chair of the congress. Each speaker shared insights cultivated through daily clinical practice and research in their respective fields of expertise. The event also featured lively discussions on global trends and future developments in aesthetic medicine, providing a valuable opportunity to deepen academic and clinical knowledge and to foster international collaboration.
Dr. Daisuke Nakamura, Chief Medical Director of Shonan Beauty Group
Dr. Kazuhiro Igawa, Representative Assistant of Shonan Beauty Group
In the rapidly evolving field of aesthetic medicine, the importance of both acquiring and sharing specialized knowledge continues to grow. As technological advancements drive increasingly diverse customer needs, it is essential not only to adopt cutting-edge technologies, but also to maintain a broad and multifaceted perspective. SBC Medical remains committed to contributing to the advancement of the aesthetic medicine industry by actively engaging with academic societies and research institutions, sharing our innovative initiatives, and incorporating the latest global knowledge and technologies into our practice.
The 113th Congress of Japan Society of Aesthetic Surgery
Venue：The Okura Tokyo
Dates：Wednesday, May 28 – Friday, May 30, 2025
Official website： https://square.umin.ac.jp/jsas113/index.html
Presentation Topics
Chair / Speaker Job Title Title
Yoshiyuki Aikawa CEO, SBC Medical Group Holdings 【Special Program/Speaker】 Practical Strategies for Cosmetic Medical Business Management and Marketing
【Special Lecture/Chair】The future of cosmetic medicine and AI
Daisuke Nakamura Chief Medical Director of Shonan Beauty Group,
Chief of Breast Augmentation at SBC 【Symposium/Speaker】Creating an attractive bust line - Fat injection breast augmentation and breast implant augmentation
Kazuhiro Igawa Representative Assistant and Technical Advisor,
Shonan Beauty Group 【Symposium/Speaker】Rhinoplasty with an awareness of harmony by considering facial parts as fonts
Ayaka Nishikawa Director of Dermatology
Department of Shonan Beauty Group 【Luncheon Seminar/Chair/Speaker】The Potential of Microneedle RF：Indications and Practical Combination Treatments in Skin Management
【Invited Lecture/Chair】Unique Treatments and Techniques with injectable Agents A 35 Year Evolution
【Symposium/Speaker】Challenges in Skin Tightening Devices: Insights from Single-Device Treatments with 6.78MHz Monopolar RF
【Sponsored Seminar/Chair】'The WHY'? -Why do we do what we do as an aesthetics injector?
【Presidential Special Program/Speaker】Evaluating the Impact of Different Approaches in Aesthetic Dermatology: A Post-Treatment Study in Identical Twins
【Sponsored Seminar/Speaker】Fine fiber sheet for application after pico-second laser treatment
Jiro Kataoka Area Medical Director and Anti-Aging Expert Doctor 【Panel Discussion/Speaker】Deep Plane Facelift for Japanese (Asians) ~My Experience and Ideas~
【Video Lecture/Chair】Fundamentals and applications of Facelift Surgery: Strategies for Addressing Age-Related Changes
Shoko Takahashi Top expert doctor in rejuvenation 【Panel Discussion/Speaker】Patient education and combination treatment to maximize patient satisfaction with thread lifting
Hiroaki Takizawa Area Doctor and Director of Jiyugaoka Clinic 【Symposium/Speaker】Revision after double eyelid surgery with sub-brow blepharoplasty
Eiko Tanaka Director of Takatsuki Hospital 【Symposium/Chair/Speaker】Innovative Approaches to Improve Labia Majora Laxity: Minimizing Scars in Reduction Surgery
Atsushi Hayashi Chief Technical Director 【Panel Discussion/Speaker】Incidence of Post-inflammatory Hyperpigmentation with Picosecond Laser in Patients with Melasma
Kanako Misono Slimming Expert Doctor 【Luncheon Seminar/Speaker】Cutting edge of Cryolipolysis: Maximize patient satisfaction with Coolsculpting
Soichiro Morikawa Anti-aging treatment expert doctor 【Luncheon Seminar/Speaker】Polynucleotide products and Hyaluronic Acid Filler
Poster Presentations
Speaker Job Title Title
Hiroshi Ohji ー Usefulness of preoperative ultrasound examination in submandibular liposuction.
Ayano Okuda Expert doctor in gynecological plastic surgery Diversifying Intimate Area Treatments ~Changes and Current Status of Pubic Hair Removal and Female Genital plastic surgery at Our Clinic~
Go Kanazawa Director of Hiroshima Clinic and Area Doctor for Hiroshima Area Lessons learned from the experience of removing limps formed by fat injection into the lower eyelid
Kaito Kuzushima Ginza Clinic Director
Top Expert Doctor in Liposuction Asian Buttocks Contouring：witout fat injection 【Evaluated with 3D Vectra】
Aiko Ssasaki Kawagoe Area Area
Doctor and Director of Kawagoe Clinic Comparison of eyelid functions before and after completely transconjunctival embedding double eyelid blepharoplasty
Yuka Takeda Director of the Esaka Institute The usefulness of next generation needle Nanosoft Microneedles
Lifting Effects and Technical Innovations in Full-Face Autologous Fat Grafting
Ryuji Tanaka Hokkaido/Tohoku Area General Manager Approach to the Management of Lower Eyelid Hollowness with Skin Laxity
Mei Nakayama ー Bilateral symmetrical enlargement within a few months after upper arm liposuction : case report
Ayaka Nishikawa Director of Dermatology
Department of Shonan Beauty Group Fine fiber sheet for application after pico-second laser treatment
Yu Hirata Director of Okayama Clinic and Area Doctor for Okayama Area Study on the direction of fat repositioning in transconjunctival blepharoplasty.
Takashi Yamamoto Director of Nagoya Institute Examination of the effects, satisfaction, and risks of orbital fat removal combined with the buried double method
Akihiro Yoshida ー Tips to improve the success rate of transconjunctival double eyelid blepharoplasty suture removal
About SBC Medical
SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. For more information, visit https://sbc-holdings.com/
Contacts
In Asia:
SBC Medical Group Holdings Incorporated
Hikaru Fukui / Head of Investor Relations
E-mail: ir@sbc-holdings.com
In the US:
ICR LLC
Bill Zima / Managing Partner
Email: bill.zima@icrinc.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
7 hours ago
- Globe and Mail
Ovarian Cancer Market Forecast to 2034: Advancing Treatment Frontiers and Epidemiological Shifts
Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific symptoms and a lack of effective early screening. It encompasses a spectrum of histological subtypes, including high-grade serous (HGSOC), low-grade serous (LGSOC), and epithelial tumors, each with unique biological and clinical features. High recurrence rates and poor long-term survival continue to drive the urgent need for improved treatment options and earlier detection. DelveInsight's latest report, ' Ovarian Cancer – Market Insight, Epidemiology, and Market Forecast – 2034,' provides a comprehensive overview of the disease's burden across the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. It offers in-depth segmentation by subtype, stage, age group, and biomarker status, alongside historical and projected epidemiological trends. The analysis highlights rising incidence rates, shifting subtype proportions—particularly serous carcinomas—and the evolving landscape of diagnostic and therapeutic innovation. The ovarian cancer market has transformed in recent years, driven by the expanding use of PARP inhibitors, antiangiogenic agents, and emerging targeted therapies. These options have shifted the treatment paradigm, particularly for BRCA-mutated, HRD-positive, and platinum-sensitive disease. Nonetheless, persistent issues such as chemoresistance, limited options in late-line settings, and variability in biomarker testing are hindering further progress. Looking ahead, the market is anticipated to grow steadily through 2034, propelled by innovations in epigenetic modulators, antibody-drug conjugates (ADCs), immune-oncology combinations, and advanced diagnostics like liquid biopsies. Enhanced biomarker testing and personalized treatment strategies will support optimized patient care. DelveInsight's full report explores pipeline highlights, market drivers and barriers, and strategic recommendations for stakeholders aiming to transform the outlook for ovarian cancer patients. Request a sample and uncover the latest breakthroughs shaping the Ovarian Cancer market landscape and future outlook Some of the key insights of the Ovarian Cancer Market Report: • In 2024, the ovarian cancer market in the 7MM was valued at USD 2.7 billion. • Market size is expected to grow with the launch of new ovarian cancer therapies. • The U.S. held the largest share, reaching USD 1.92 billion in 2024. • Total incident ovarian cancer cases in the 7MM were 61K in 2024. • The U.S. reported the highest number of high and low-grade serous ovarian cancer cases. • There were approximately 37.6K serous ovarian cancer cases in the 7MM in 2024. • In January 2025, IPS HEART received Orphan Drug Designation (ODD) from the FDA for GIVI-MPCs, recognizing their potential to create new muscle with full-length dystrophin in Becker Muscular Dystrophy (BMD). The therapy has shown promising results in generating human muscle with full-length dystrophin in dystrophic pigs, young and aged Duchenne Muscular Dystrophy (DMD) mice, and an Ovarian Cancer mouse model. • In April 2025, Biocon Biologics received FDA approval for JOBEVNE (bevacizumab-nwgd), a biosimilar to Avastin®, for intravenous use. JOBEVNE is approved for multiple cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and ovarian, fallopian tube, or primary peritoneal cancer. • In February 2025, the FDA granted fast-track designation to CUSP06, a CDH6-directed antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant ovarian cancer. • Emerging therapies for ovarian cancer include Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others. • Key companies involved in the treatment of ovarian cancer include Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others. Curious to see the graphical version of these numbers? The ovarian cancer infographic is ready for you. Check it out here! Ovarian Cancer Overview Ovarian cancer is a complex and often late-diagnosed malignancy arising from the epithelial cells, stromal cells, or germ cells of the ovary. Among these, epithelial ovarian cancer is the most prevalent, accounting for over 90% of malignant ovarian tumors. Due to its subtle early symptoms and lack of reliable screening methods, the disease is frequently diagnosed at advanced stages, contributing to its high mortality rate among gynecological cancers. The most common and aggressive subtype is High-Grade Serous Ovarian Cancer (HGSOC), which often presents with widespread peritoneal metastases. In contrast, Low-Grade Serous Ovarian Cancer (LGSOC) tends to follow a more indolent course but shows resistance to standard chemotherapy, highlighting a critical unmet need for targeted therapies. Genetic mutations such as BRCA1/2 and alterations in the MAPK pathway (BRAF/KRAS/NRAS/NF1) and homologous recombination deficiency (HRD) status play a pivotal role in disease stratification and therapy selection. Over the past decade, the ovarian cancer treatment landscape has evolved with the introduction of PARP inhibitors, anti-angiogenic agents, and targeted therapies that have significantly improved outcomes in biomarker-driven subpopulations. Despite these advancements, resistance development, limited options for certain subtypes like LGSOC, and high relapse rates continue to challenge long-term disease control. As research progresses, efforts are focused on improving early diagnosis, personalizing treatment based on molecular profiling, and expanding therapeutic options through clinical trials and novel drug development. Get a free sample for the Ovarian Cancer market forecast, size & share analysis report: Ovarian Cancer Epidemiology The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends. Ovarian Cancer Epidemiology Segmentation: The Ovarian Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: • Total incident cases of Ovarian Cancer • Age-specific cases of Ovarian Cancer • Type-Specific Cases of Ovarian Cancer • Stage-specific Cases of high and Low-Grade Serous Ovarian Cancer • Biomarker-specific Cases of high and Low-Grade Serous Ovarian Cancer Ovarian Cancer Drugs Uptake and Pipeline Development Activities The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for Ovarian Cancer throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments. The Therapeutics Assessment further highlights the Ovarian Cancer drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction. Additionally, the report provides an in-depth overview of the current therapeutic pipeline for Ovarian Cancer, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of Ovarian Cancer therapeutics. Ovarian Cancer Market Outlook The ovarian cancer treatment landscape is undergoing a significant transformation, with the integration of targeted therapies, personalized medicine, and ongoing clinical research aimed at improving long-term outcomes. High-grade serous ovarian cancer (HGSOC), the most prevalent subtype, continues to be treated with a combination of surgery and platinum-based chemotherapy. However, the emergence of maintenance therapies—especially PARP inhibitors—has reshaped post-treatment strategies for patients with BRCA or HRD mutations, helping reduce recurrence rates and extend progression-free survival. The future of ovarian cancer care is increasingly personalized, with clinical trials exploring novel options like immunotherapy, vaccine-based approaches, and radiation strategies for advanced or recurrent disease. These innovations reflect a broader trend toward therapies tailored to molecular profiles and disease stage, moving away from one-size-fits-all treatment. However, disparities in access to care remain a major challenge. Socioeconomic, racial, and geographic barriers often limit timely diagnosis and appropriate treatment, particularly in underserved populations. As awareness of BRCA testing and biomarker-driven treatment grows, expanding access to genetic screening and oncology expertise will be crucial. The ovarian cancer market is expected to expand steadily through 2034, driven by rising disease burden, evolving therapeutic options, and a growing emphasis on precision medicine. Addressing current gaps in care delivery, especially among high-risk and underserved groups, will be essential to unlocking the full potential of these medical advancements. Ovarian Cancer Market Drivers • The introduction of PARP inhibitors (e.g., olaparib, niraparib) and other targeted agents based on BRCA and HRD status has revolutionized ovarian cancer treatment, improving survival and reducing recurrence in select patient groups. • Increasing adoption of genetic and molecular testing for BRCA mutations, HRD status, and other biomarkers is enabling personalized treatment strategies, driving demand for advanced therapeutic options. Ovarian Cancer Market Barriers • The absence of reliable early screening methods and vague initial symptoms often lead to diagnosis at advanced stages, limiting curative treatment options and affecting patient outcomes. • Limited access to specialized oncology care, especially in rural and low-income regions, along with underutilization of genetic testing among minority populations, continues to hinder equitable treatment and diagnosis. Scope of the Ovarian Cancer Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]. • Key Ovarian Cancer Companies: Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others. • Key Ovarian Cancer Therapies: Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others. • Ovarian Cancer Therapeutic Assessment: Ovarian Cancer currently marketed, and Ovarian Cancer emerging therapies. • Ovarian Cancer Market Dynamics: Ovarian Cancer market drivers and Ovarian Cancer market barriers. • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies. • Ovarian Cancer Unmet Needs, KOL's views, Analyst's views, Ovarian Cancer Market Access and Reimbursement. Table of Contents 1. Ovarian Cancer Market Report Introduction 2. Executive Summary for Ovarian Cancer 3. SWOT analysis of Ovarian Cancer 4. Ovarian Cancer Patient Share (%) Overview at a Glance 5. Ovarian Cancer Market Overview at a Glance 6. Ovarian Cancer Disease Background and Overview 7. Ovarian Cancer Epidemiology and Patient Population 8. Country-Specific Patient Population of Ovarian Cancer 9. Ovarian Cancer Current Treatment and Medical Practices 10. Ovarian Cancer Unmet Needs 11. Ovarian Cancer Emerging Therapies 12. Ovarian Cancer Market Outlook 13. Country-Wise Ovarian Cancer Market Analysis (2020–2034) 14. Ovarian Cancer Market Access and Reimbursement of Therapies 15. Ovarian Cancer Market Drivers 16. Ovarian Cancer Market Barriers 17. Ovarian Cancer Appendix 18. Ovarian Cancer Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Globe and Mail
8 hours ago
- Globe and Mail
2 No-Brainer Artificial Intelligence Stocks to Buy Right Now
No matter where you are on the artificial intelligence (AI) debate -- for or against -- there's no denying that it's transforming the way people work. Companies of all shapes and sizes are integrating into their daily workflows, and new industries are popping up because of it. The mass adoption of AI could result in a market size of more than $15 trillion by 2030, according to PwC research. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Fortunately, there are tons of AI companies out there that actually have a foothold in the market and aren't just flash-in-the-pan opportunities. Here are two well-established companies that are already benefiting from this trend and could be great AI stocks for years to come. 1. Taiwan Semiconductor Taiwan Semiconductor Manufacturing (NYSE: TSM) does exactly what its name describes -- it manufactures processors for companies. The world's leading chip designers, including Nvidia, rely on Taiwan Semiconductor (often referred to as TSMC) to make their processors because the company is so good at it. TSMC manufactures an estimated 90% of the world's artificial intelligence semiconductors, making it the clear leader in this market. This dominance led to TSMC's revenue rising 41% in the first quarter of 2025 to $25.5 billion and diluted earnings per share jumping 60% to $2.12 per American depository receipt (ADR). TSMC relies on its technological lead in semiconductor manufacturing to stay ahead of its competitors, and so far, it's still leading the pack. The company is focused on its 5-nanometer (nm) and 3nm chip production and management said recently that there continues to be "strong demand" for both. The company's CEO, C.C. Wei, said early this year he expects TSMC's artificial intelligence revenue to double this year compared to last year and recently reiterated that forecast. Taiwan Semiconductor stock has already gained 142% over the past three years, so what makes the stock a buy right now? Demand for semiconductors hasn't slowed down yet, and no one knows when or if it will. Companies are locked in an AI race right now, and a big part of that involves getting their hands on the most advanced AI chips. With TSMC's dominance in semiconducting manufacturing and it already holding a lead in advanced AI processors, the company is poised to benefit from chip demand as long as tech giants need the best processors available. And despite its share price gains, TSMC stock has a price to earnings ratio of just 25, which is below the P/E multiple of the broader S&P 500. 2. Microsoft Microsoft (NASDAQ: MSFT) has made itself an important player in artificial intelligence by making strategic investments in ChatGPT creator OpenAI over the past several years. The early move gave Microsoft access to one of the most advanced AI chatbots on the market, and it quickly implemented ChatGPT into everything from its Microsoft 365 suite of productivity tools to its GitHub Copilot coding assistant. That's helped Microsoft stay relevant in a rapidly shifting tech market and benefit from AI's growth. Part of Microsoft's AI strategy has been to offer more advanced services with its Azure cloud computing platform, which has helped result in a 35% jump in cloud services sales in the fiscal third quarter (which ended March 31). Microsoft is the second-largest public cloud computing provider with 21% market share, trailing only Amazon, which holds 30%. Microsoft has narrowed this gap over the past few years, and its investments in artificial intelligence infrastructure could make it an even stronger contender. The company will spend $80 billion on cloud infrastructure this fiscal year alone to stay ahead of the competition. Microsoft's stock is a bit more expensive than Taiwan Semiconductor's, with a P/E multiple of 36. But with Microsoft already off to a strong start in implementing advanced AI into its software and benefiting from AI cloud services, the company is setting itself up to remain a leading tech player for years to come. Should you invest $1,000 in Taiwan Semiconductor Manufacturing right now? Before you buy stock in Taiwan Semiconductor Manufacturing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Taiwan Semiconductor Manufacturing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor 's total average return is995% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Chris Neiger has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Microsoft, Nvidia, and Taiwan Semiconductor Manufacturing. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Globe and Mail
8 hours ago
- Globe and Mail
Precious metals: platinum edition
Platinum has recently captured market attention with a notable price breakout, definitively pushing above US$1,100 per ounce, after spending much of this decade rangebound between US$850-$1,100 per ounce. A primary catalyst for this shift in platinum's fortunes lies in the evolving landscape of the automotive industry. For years, the anticipated dominance of electric vehicles (EVs) cast a long shadow over platinum demand, given that approximately one-third to nearly half of its use is in catalytic converters for internal combustion engines. However, a significant pivot is underway. Auto original equipment manufacturers (OEMs) are now re-evaluating and scaling back ambitious EV targets, instead placing a renewed emphasis on hybrid engines. Growing demand This may be a considerable boon for platinum, not only because hybrids still incorporate catalytic converters, but critically, these vehicles demand more platinum per unit. The start-stop technology and extended battery-only operation in hybrids mean their catalytic converters often run at lower temperatures, requiring a higher concentration of platinum to maintain optimal efficiency. Beyond the automotive sector, robust jewelry demand is providing substantial support to platinum's price. Historically, a price increase might dampen jewelry sales, but in the current environment, particularly in key markets like China, demand remains strong. A significant factor here is the compelling price disparity between platinum and gold. With platinum currently trading at approximately one-third the price of gold, a substantial gap exists, making platinum jewelry an attractive alternative. This stark difference suggests that jewelry demand is not only supportive of the current breakout but has the potential to further bolster the demand side of the equation. Platinum/gold ratio shifting Adding another layer to this positive narrative is the recent upward trend in the platinum-to-gold ratio. This ratio, which had seen a prolonged decline partly fueled by the 'platinum is dead' narrative linked to EV expectations, is now signaling a change in investor sentiment. The recent movement of platinum outpacing gold suggests that investors are increasingly looking for value beyond traditional safe havens and may be diversifying into platinum as a store of value. In summary, platinum's recent price surge is underpinned by several powerful forces. These include a turn to positive net long positions among traders, a fundamental shift in the auto industry towards hybrid vehicles, sustained strong jewelry demand driven by an attractive price differential with gold, and a notable re-evaluation of platinum's investment appeal relative to gold. Collectively, these factors suggest a robust and potentially lasting upward trajectory for the metal. John Kratochwil, MBA, is Senior Analyst at AGF Management Ltd. specializing in the Materials (ex-Chemicals) and Real Estate sectors. Notes and Disclaimer Content copyright © 2025 by AGF Ltd. This article first appeared in AGF Perspectives. Reprinted with permission. The views expressed are those of the author and do not necessarily represent the opinions of AGF, its subsidiaries or any of its affiliated companies, funds, or investment strategies. Commentary and data sourced from Bloomberg, Reuters and other news sources unless otherwise noted. The commentaries contained herein are provided as a general source of information based on information available as of June 10, 2025. It is not intended to address the needs, circumstances, and objectives of any specific investor. The content of this commentary is not to be used or construed as investment advice, as an offer to buy or sell any securities, and is not intended to suggest taking or refraining from any course of action. Every effort has been made to ensure accuracy in these commentaries at the time of publication, however, accuracy cannot be guaranteed. Market conditions may change and AGF Investments accepts no responsibility for individual investment decisions arising from the use or reliance on the information contained herein. This document may contain forward-looking information that reflects our current expectations or forecasts of future events. Forward-looking information is inherently subject to, among other things, risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed herein. For Canadian investors: Commissions, trailing commissions, management fees and expenses all may be associated with investment fund investments. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated. AGF Investments is a group of wholly owned subsidiaries of AGF Management Limited, a Canadian reporting issuer. The subsidiaries included in AGF Investments are AGF Investments Inc. (AGFI), AGF Investments America Inc. (AGFA), AGF Investments LLC (AGFUS) and AGF International Advisors Company Limited (AGFIA). AGFI is registered as a portfolio manager across Canadian securities commissions. AGFA and AGFUS are registered investment advisors with the U.S. Securities Exchange Commission. AGFIA is regulated by the Central Bank of Ireland and registered with the Australian Securities & Investments Commission. The term AGF Investments may refer to one or more of these subsidiaries or to all of them jointly. This term is used for convenience and does not precisely describe any of the separate companies, each of which manages its own affairs. AGF Investments entities only provide investment advisory services or offers investment funds in the jurisdiction where such firm, individuals and/or product is registered or authorized to provide such services. Investment advisory services for U.S. persons are provided by AGFA and AGFUS. In connection with providing services to certain U.S. clients, AGF Investments LLC uses the resources of AGF Investments Inc. acting in its capacity as AGF Investments LLC's 'participating affiliate', in accordance with applicable guidance of the staff of the SEC. AGFA engages one or more affiliates and their personnel in the provision of services under written agreements (including dual employee) among AGFA and its affiliates and under which AGFA supervises the activities of affiliate personnel on behalf of its clients ('Affiliate Resource Arrangements'). ® ™ The 'AGF' logo and all associated trademarks are registered trademarks or trademarks of AGF Management Limited and used under licence.
